Ketoconazole
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1981
- First approval year
- 1981
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Ketoconazole
- Molecular weight
- 531.44
- Structure (SMILES)
- CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
- daktarin gold
- Daktarin gold
- daktarin intensiv
- Daktarin intensiv
- dandrazol
- Dandrazol
- dandrid
- Dandrid
- extina
- Extina
- ketoconazole
- Ketoconazole
- ketoconazole hra
- Ketoconazole hra
- ketopine
- Ketopine
- ketozole
- Ketozole
- nizoral
- Nizoral
- nizoral a d
- Nizoral a-d
- nizoral anti dandruff
- Nizoral anti-dandruff
- nizorelle
And 3 more, listed on the interactive page.
- (±)-CIS-1-ACETYL-4-(P-((2-(2,4-DICHLOROPHENYL)-2-(IMIDAZOL-1-YLMETHYL)-1,3-DIOXOLAN-4-YL)METHOXY)PHENYL)PIPERAZINE
- cis 1 acetyl 4 p 2 2 4 dichlorophenyl 2 imidazol 1 ylmethyl 1 3 dioxolan 4 yl methoxy phenyl piperazine
- j02ab02
- J02AB02
- ketoconazol
- Ketoconazol
- ketoconazole
- Ketoconazole
- KETOCONAZOLE [EP IMPURITY]
- KETOCONAZOLE [EP MONOGRAPH]
- KETOCONAZOLE [HSDB]
- ketoconazole [INN]
- KETOCONAZOLE [JAN]
- KETOCONAZOLE [MART.]
- KETOCONAZOLE [MI]
- KETOCONAZOLE [ORANGE BOOK]
- KETOCONAZOLE [USAN]
- KETOCONAZOLE [USP IMPURITY]
- KETOCONAZOLE [USP MONOGRAPH]
- KETOCONAZOLE [USP-RS]
- KETOCONAZOLE [VANDF]
- Ketoconazole [WHO-DD]
- ketoconazole ep impurity
- ketoconazole ep monograph
- ketoconazole hsdb
And 27 more, listed on the interactive page.
- CAS registry numbers
- 65277-42-1
- ChEMBL ID
- CHEMBL157101
- InChIKey
- XMAYWYJOQHXEEK-UHFFFAOYSA-N
- PubChem compound IDs
- 3823
- RxNorm IDs (RxCUI)
- 6135
- FDA ingredient codes (UNII)
- R9400W927I
- D01AC08
- G01AF11
- H02CA03
- J02AB02
- V03
Sources for recorded values
- Applicant
- KRAMER
- Approval date
- 10 Oct 1997
- Application number
- NDA020310
- Status
- Authorised
- Status date
- 18 Nov 2014
- Authorisation date
- 18 Nov 2014
- Approved indications
- Ketoconazole Esteve is indicated for the treatment of endogenous Cushing’s syndrome in adults and adolescents above the age of 12 years.
- Product number
- EMEA/H/C/003906
- Authorisation holder
- Esteve Pharmaceuticals, S.A.
- Priority medicines scheme
- No
- Generic
- No
- Biosimilar
- No
- Generic medicines
- 0
- Biosimilar medicines
- 0
- Advanced therapy
- No
- Conditional approval
- No
- Additional monitoring
- Yes
- Accelerated assessment
- Yes
- Exceptional circumstances
- No
Therapeutic areas
- Cushing Syndrome
European medicines record
- Patents
- 0
- Designations
- 1
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Over the counter
- Boxed warning
- Yes
- United States (FDA)
- Approved
- European Union (EMA)
- Authorised
- Pharmacology name
- ketoconazole
- Type
- Synthetic organic
- Drug name stem
- -conazole
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Oral
- topical
- Action
- Channel blocker
- Action type
- Channel blocker
- Target
- Kv1.8
- Gene symbol
- KCNA10
- Protein identifier
- Q16322
- Median affinity
- 6.3
- Affinity units
- pIC50
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- CYP3A4
- Gene symbol
- CYP3A4
- Protein identifier
- P08684
- Median affinity
- 7
- Affinity units
- pKi
- Mechanism
- Cytochrome P450 51 inhibitor
- Action type
- Inhibitor
- Target
- Lanosterol 14-alpha demethylase
- Protein identifier
- P10613
Open Targets mechanisms
- Mechanism
- Cytochrome P450 51 inhibitor
- Action type
- Inhibitor
- Target
- Lanosterol 14-alpha demethylase
- Action type
- Blocker
- Gene symbol
- KCNA10
- Protein identifier
- Q16322
- Organism
- Homo sapiens
- Target development level
- Clinical
- Action type
- Inhibitor
- Gene symbol
- CYP17A1
- Protein identifier
- P05093
- Organism
- Homo sapiens
- Target development level
- Clinical
- Action type
- Inhibitor
- Gene symbol
- ERG11
- Protein identifier
- P10613
- Organism
- Candida albicans (strain SC5314 / ATCC MYA-2876)
- Action type
- Inhibitor
- Gene symbol
- CYP11B1
- Protein identifier
- P15538
- Organism
- Homo sapiens
- Target development level
- Clinical
- Action type
- Inhibitor
- Gene symbol
- CYP11B2
- Protein identifier
- P19099
- Organism
- Homo sapiens
- Target development level
- Chemical evidence
- Condition
- Leukemia, Lymphocytic, Chronic, B-Cell
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000095
- Subject identifier
- D015451
- Condition
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000339
- Subject identifier
- D015464
- Condition
- Pulmonary Disease, Chronic Obstructive
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000341
- Subject identifier
- D029424
- Condition
- Glioblastoma
- Highest recorded phase
- 0.5
- Condition identifier
- EFO:0000519
- Subject identifier
- D005909
- Condition
- Immune System Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000540
- Subject identifier
- D007154
- Condition
- Lymphoma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000574
- Subject identifier
- D008223
- Condition
- Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Neuroblastoma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000621
- Subject identifier
- D009447
- Condition
- Prostatic Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000673
- Subject identifier
- D011471
- Condition
- Melanoma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000756
- Subject identifier
- D008545
- Condition
- Prostatic Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0001663
- Subject identifier
- D011471
- Condition
- Insulin Resistance
- Highest recorded phase
- 0.5
- Condition identifier
- EFO:0002614
- Subject identifier
- D007333
- Condition
- Hepatitis C
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003047
- Subject identifier
- D006526
- Condition
- Cushing Syndrome
- Highest recorded phase
- 4
- Condition identifier
- EFO:0003099
- Subject identifier
- D003480
- Condition
- Osteoporosis
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003882
- Subject identifier
- D010024
- Condition
- Acne Vulgaris
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003894
- Subject identifier
- D000152
- Condition
- Premature Birth
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003917
- Subject identifier
- D047928
- Condition
- Vaginosis, Bacterial
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003932
- Subject identifier
- D016585
- Condition
- Erectile Dysfunction
- Highest recorded phase
- 1
- Condition identifier
- EFO:0004234
- Subject identifier
- D007172
- Condition
- Adrenal Gland Diseases
- Highest recorded phase
- 4
- Condition identifier
- EFO:0005539
- Subject identifier
- D000307
- Condition
- Lymphoma, Non-Hodgkin
- Highest recorded phase
- 1
- Condition identifier
- EFO:0005952
- Subject identifier
- D008228
- Condition
- Nausea
- Highest recorded phase
- 1
- Condition identifier
- EFO:0006911
- Subject identifier
- D009325
- Condition
- Blastomycosis
- Highest recorded phase
- 4
- Condition identifier
- EFO:0007174
- Subject identifier
- D001759
- Condition
- Tinea Versicolor
- Highest recorded phase
- 1
- Condition identifier
- EFO:0007439
- Subject identifier
- D014010
- Condition
- Tinea
- Highest recorded phase
- 4
- Condition identifier
- EFO:0007510
- Subject identifier
- D014005
And 19 more, listed on the interactive page.
- Condition identifier
- EFO_0000339
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000341
- Highest recorded phase
- 1
- Condition identifier
- EFO_0000519
- Condition identifier
- EFO_0000540
- Highest recorded phase
- 1
- Condition identifier
- EFO_0000616
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000756
- Highest recorded phase
- 1
- Condition identifier
- EFO_0003099
- Condition identifier
- EFO_0003894
- Highest recorded phase
- 3
- Condition identifier
- EFO_0004234
- Highest recorded phase
- 1
- Condition identifier
- EFO_0005539
- Condition identifier
- EFO_0006461
- Highest recorded phase
- 2
- Condition identifier
- EFO_0007174
- Condition identifier
- EFO_0007439
- Highest recorded phase
- 1
- Condition identifier
- EFO_0007510
- Condition identifier
- EFO_0007512
- Condition identifier
- EFO_0007543
- Highest recorded phase
- 3
- Condition identifier
- EFO_0009363
- Highest recorded phase
- 2
- Condition identifier
- EFO_0009784
- Highest recorded phase
- 2
- Condition identifier
- EFO_1000764
- Condition identifier
- EFO_1001494
- Highest recorded phase
- 2
- Condition identifier
- GO_0042060
- Highest recorded phase
- 2
- Condition identifier
- HP_0000027
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0001134
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0001628
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0002026
- Highest recorded phase
- 3
And 45 more, listed on the interactive page.
- Warning
- Black Box Warning
- Effect
- cardiotoxicity
- Warning
- Black Box Warning
- Effect
- hepatotoxicity
- Warning
- Withdrawn
- Effect
- hepatotoxicity
- Description
- Liver toxicity is more frequent and severe than with other antifungal treatments; Elevated risk of early onset liver damage
- Year
- 2011
- Warning
- Black Box Warning
- Effect
- cardiotoxicity
- Country
- United States
- Warning
- Black Box Warning
- Effect
- hepatotoxicity
- Country
- United States
- Warning
- Withdrawn
- Effect
- hepatotoxicity
- Description
- Liver toxicity is more frequent and severe than with other antifungal treatments; Elevated risk of early onset liver damage
- Year
- 2011
- Country
- Guatemala; Madagascar
- Condition
- drug-induced liver injury
- Warning
- Withdrawn
- Effect
- hepatotoxicity
- Description
- Liver toxicity is more frequent and severe than with other antifungal treatments; Elevated risk of early onset liver damage
- Year
- 2011
- Country
- Guatemala; Madagascar
- Condition
- hepatotoxicity
- Event
- abortion spontaneous
- Reports
- 33
- Reporting signal score
- 43.1054
- Event
- adrenal insufficiency
- Reports
- 25
- Reporting signal score
- 58.573
- Event
- alanine aminotransferase increased
- Reports
- 35
- Reporting signal score
- 31.4507
- Event
- alcohol intolerance
- Reports
- 7
- Reporting signal score
- 28.2187
- Event
- aspartate aminotransferase increased
- Reports
- 34
- Reporting signal score
- 33.053
- Event
- bladder dilatation
- Reports
- 5
- Reporting signal score
- 15.409
- Event
- blood alkaline phosphatase increased
- Reports
- 16
- Reporting signal score
- 16.2414
- Event
- blood chloride decreased
- Reports
- 8
- Reporting signal score
- 19.1983
- Event
- cholestasis
- Reports
- 14
- Reporting signal score
- 15.1155
- Event
- colour vision tests normal
- Reports
- 3
- Reporting signal score
- 21.4526
- Event
- contraindication to medical treatment
- Reports
- 11
- Reporting signal score
- 40.9882
- Event
- cortisol increased
- Reports
- 9
- Reporting signal score
- 46.0676
- Event
- deafness bilateral
- Reports
- 8
- Reporting signal score
- 23.8348
- Event
- drug interaction
- Reports
- 137
- Reporting signal score
- 189.729
- Event
- hepatic necrosis
- Reports
- 8
- Reporting signal score
- 18.8563
- Event
- hepatitis
- Reports
- 20
- Reporting signal score
- 24.8742
- Event
- hepatitis cholestatic
- Reports
- 9
- Reporting signal score
- 15.7669
- Event
- hepatotoxicity
- Reports
- 28
- Reporting signal score
- 50.5472
- Event
- hypokalaemia
- Reports
- 27
- Reporting signal score
- 28.0871
- Event
- jaundice
- Reports
- 22
- Reporting signal score
- 27.2227
- Event
- mixed liver injury
- Reports
- 11
- Reporting signal score
- 31.7883
- Event
- multiple chemical sensitivity
- Reports
- 4
- Reporting signal score
- 21.444
- Event
- pneumonia mycoplasmal
- Reports
- 8
- Reporting signal score
- 29.8381
- Event
- premature rupture of membranes
- Reports
- 9
- Reporting signal score
- 23.257
- Event
- prostate cancer metastatic
- Reports
- 6
- Reporting signal score
- 16.5065
And 10 more, listed on the interactive page.
- NCT00000579
- NCT00002760
- NCT00002855
- NCT00003084
- NCT00006371
- NCT00024167
- NCT00027859
- NCT00030654
- NCT00309894
- NCT00460031
- NCT00673127
- NCT00859781
- NCT00895310
- NCT00953576
- NCT01036594
- NCT02494713
- NCT03261336
- NCT00003249
- NCT00096317
- NCT00162214
- NCT00238225
- NCT00697437
- NCT01114191
- NCT01218620
- NCT01267084
And 60 more, listed on the interactive page.
- How often
- 1 to 3 times daily
- Avoid use on open wounds, cuts, or raw skin
- Do not reuse
- Thoroughly wipe the affected area
- Use a pad for each wipe
- Hydrogen bond acceptors
- 7
- Hydrogen bond donors
- 0
- Polar surface area
- 69.06
- Calculated partition coefficient (ALogP)
- 4.21
- Calculated partition coefficient (XLogP)
- 4.3
- Prodrug
- No
- Chirality
- Racemic
- Inorganic
- No
- Rule-of-five violations
- 1
- Rotatable bonds
- 7
- Heavy atoms
- 36
- Molecular formula
- C26H28Cl2N4O4
- Monoisotopic mass
- 530.1487608
- Natural product
- Yes
- 0093-3219
- 0168-0099
- 0713-0592
- 16714-955
- 21922-025
- 35573-433
- 43538-530
- 45802-465
- 45802-532
- 51407-279
- 60429-020
- 63187-774
- 63646-010
- 64380-827
- 69292-224
- 70700-160
- 70954-662
- 71205-105
- 71713-097
- 72189-180
- 72189-422
- 72189-428
- 72578-156
- 72603-878
- 72789-052
And 33 more, listed on the interactive page.
- Recorded assays
- 6,484
- Active assays
- 620
- Confirmatory
- Other
These details could not be displayed.
Related records
Trials (170)
- 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer
- A 4 Week Study of Elidel (Pimecrolimus) for the Treatment of Seborrheic Dermatitis
- A Comparison of Fluconazole and Ketoconazole in the Treatment of Fungal Infections of the Throat in Patients With Weakened Immune Systems
- A Drug Interaction Study of JNJ-31001074 and Ketoconazole in Healthy Volunteers
- A Drug Interaction Study With Fluticasone Furoate/GW642444 Inhalation Powder and Ketoconazole
- A Drug-Drug Interaction Study of Ketoconazole, Rifampicin and Ritonavir-Boosted Atazanavir With Single-Dose RO5093151 in Healthy Volunteers
- A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects of Ketoconazole and Gemfibrozil on GSK2118436, and the Effects of Repeat Doses of GSK2118436 in Subjects With BRAF Mutant Solid Tumors
- A Pharmacokinetics Study to Investigate the Effect of Ketoconazole on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma
- A Phase 1 Open-Label Study to Evaluate the Effect of CYP450 and P-gp Inhibition and Induction on the Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects
- A Phase I Study To Estimate The Effect Of Ketoconazole And Omeprazole On The Pharmacokinetics Of Dimebon In Healthy Subjects Who Are Normal Or Poor CYP2D6 Metabolizers
- A Phase II Trial of Early Medical Adrenalectomy for "D0.5" Prostate Cancer
- A Pilot Study of the Treatment of Central Serous Chorioretinopathy With Ketoconazole
- A Randomized, Multiple Dose, Double Blind, 5-way Crossover Study of the Electrocardiographic (ECG) Effects of Bilastine
- A Study Comparing Ketoconazole Shampoo, 2% and Ketoconazole 2% Shampoo (RS) in the Treatment of Tinea Versicolor.
- A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ABT-333
- A Study of Baricitinib When Administered With Ketoconazole or Fluconazole in Healthy Participants
- A Study of LY2484595 on Pharmacokinetics in Healthy Participants
- A Study of RO5190591 (Danoprevir) in Healthy Volunteers
- A Study of the Effects of Ketoconazole Taken Orally Has on the PK Profiles of a Dose of GSK189075 in Healthy Volunteers
- A Study of The Effects of Multiple Doses of Ketoconazole on Single Dose Pharmacokinetics of RO4602522 in Healthy Male Volunteers
Approved for (7)
- Adrenal gland disorder
- Blastomycosis
- Cushing syndrome
- Fungal infectious disease
- Seborrheic dermatitis
- Tinea infection
- Tinea pedis
In development for (49)
- Acne Phase 3
- Acute respiratory distress syndrome Phase 3
- Adult acute respiratory distress syndrome Phase 3
- Alzheimer disease Phase 1
- Asthma Phase 1
- Avascular necrosis Phase 2
- B-cell chronic lymphocytic leukemia Phase 1
- Bacterial vaginosis Phase 3
- Breast cancer Phase 2
- Burn Phase 2
- Cancer Phase 2
- Candidiasis Phase 3
- Chronic myeloid leukemia Phase 2
- Chronic obstructive pulmonary disease Phase 1
- Dermatitis Phase 3
- Dermatophytosis Phase 3
- Erectile dysfunction Phase 1
- Essential hypertension Phase 1
- Gastroparesis Phase 1
- Glioblastoma Early phase 1
Other linked conditions (3)
- Cryptorchidism
- Delirium
- Dermatophytosis of scalp or beard